This evening!

Evolution of MDS Management Hinges on Standardized Disease Classification, Molecularly Informed Risk Stratification @carrawayhetty.bsky.social @clevelandclinic.bsky.social #MDS #mdssm www.onclive.com/view/evoluti...

What a fantastic night for dreams coming true! Can't wait to watch all of their journeys continue!

More researchers are now eligible for the ASH Bridge Grant! With NIH funding cuts disrupting study sections, ASH expanded eligibility for midcareer investigators. Learn how ASH is taking action to support hematology researchers: https://bit.ly/4hW5arC #ASHAwards #Fight4Hematology #HemeSky

Cutting HHS staff to “save money” is like firing all the firefighters to lower the city’s water bill - it makes no damn sense Staff are less than 1% of the HHS budget - but they’re the ones who respond when there’s a fire They’re not saving money. They’re letting it (our health) all burn 🚒💨 🔥🏥🔥

Paige Bueckers has set a new UConn WBB record for points in an NCAA Tournament game in today's win over Oklahoma 🔥 ◽ 40 PTS ◽ 16/27 FG ◽ 6/8 3-PT FG

A review on the role of #MDM2 in regulating the #ImmuneMicroenvironment, tumor #ImmuneEvasion, & hyperprogression during #immunotherapy, with insights on the application of MDM2 inhibitors in combination with immunotherapy in tumors with MDM2 overexpression. #medsky www.sciencedirect.co...#MDM2#ImmuneMicroenvironment,

My first @bloodjournal.bsky.social article!

Happy to share our work published in Nature Medicine! We analyzed 3,066 patients from the French DESCAR-T registry who received #CARTcell therapy. Our findings indicate a very low risk of T-cell malignancy after CAR T-cell therapy: only 1 case (0.03%). www.nature.com/articles/s41...

How I Do It: Interpreting Clinical Trial Results An excellent rubric for understanding and interpreting randomized clinical trials in #journal_CHESTCritCare: hubs.la/Q030pjgL0 #JournalCHEST

10 Questions With Kaitlyn Dykes, chair of #ASHTrainee Council 📰In this ASH News Daily article, Dr. Dykes is asked "Who's your ASH-lebrity/the ASH luminary you most admire?" Read more for the answer. And tell us: who's your ASH-lebrity? https://bit.ly/3ZIzD5G#ASHTrainee#ASH24 #HemeSky #Hematology

Cancer prevention is one of the most critical challenges of our time - Karen Knudsen @drkarenknudsen.bsky.social oncodaily.com/blog/215298 #Medicine #Health #Oncology #OncoDaily #Cancer

My New Year’s resolution is to berate myself less for things I wish I could have done better, to learn from my mistakes, and give myself more credit for the things I did well but promptly forgot/ignored because academics love to live from crisis to crisis

Our assessment of a person's epigenetic ("biological") age has been centered on DNA methylation. A new report shows that a set of 7 histone markers has comparable accuracy and also uncovers new pathways of aging biology www.science.org/doi/10.1126/...

Most previous epigenetic age predictors were focused on DNA methylation. Our own model suggested nucleosome positioning as an age predictor a year ago onlinelibrary.wiley.com/doi/full/10....

Bioart, courtesy of the NIH. All images are in the public domain and available for download as high-quality SVGs. bioart.niaid.nih.gov

As an oncologist, I get constant reminders that holidays are joyful & meaningful milestones, but not every yr & not for everyone. If you are with #grief, I hope this will remind you that you belong to something vast & are not alone. #MedSky #OncSky #LongCovid www.nytimes.com/2024/12/20/s...

The most complete collection of uniformly processed ChIP-seq data on identification of transcription factor binding sites for human and mouse. Convenient web interface with advanced search, browsing and genome browser based on the BioUML platform. gtrd.biouml.org/

💡 Why mentor with ASH? • Inspire future hematologists • Foster career growth • Address workforce shortages Apply by January 9: https://bit.ly/3VLCPwb #ASHTrainee #Hematology #Mentor #HemeSky #Bloodsky 🩸

Although still in 'First Edition' style, I am happy to finally share our latest article on DNMT3A double mutant AML. Hope to be able to share the way-easier-to-read print version of the paper soon! (1/2) #hemesky ashpublications.org/bloodadvance...

The FDA has approved BRAFTOVI in combination with cetuximab and mFOLFOX6 for first-line treatment in patients with metastatic colorectal cancer with a BRAF V600E mutation. The approval is based on the BREAKWATER study, for which MD Anderson’s Dr. Scott Kopetz is co-PI. 1/2

🩸Erythropoiesis #medsky #IMsky #internalmedicine #hemesky #hematology #heme #physiology #manualofmedicine

🩸Hematopoietic stem cell differentiation with cytokine regulation #hemesky #hemeonc #medsky #IMsky #internalmedicine #hemepath #pathsky #stemcells

💊 Chemotherapy: disrupting cancer cell cell growth and survival at multiple levels. This handy diagram summarizes chemotherapy classes and where they fit according to their mechanism of action ⚙️ #oncsky #hemeonc #hemesky #pharmsky #medsky #IMsky #cancer #chemo (Falzone et al., 2023. Cell)

🩸 Febrile Non-Hemolytic (FNHTR): - Time: ≤ 4 hours - Cause: cytokines in donor blood - Prevention: H2 blockers, antipyretics, leukoreduction - Mgmt: stop infusion, antipyretrics, H2 blockers, meperidine (rigors), r/o other causes, notify blood bank #hemesky #medsky #IMsky #internalmedicine

🫀Cardiac tamponade vs constrictive pericarditis vs restrictive cardiomyopathy A big thanks to #IMR for this handy comparison table. Good for reference down the road or for someone like myself currently studying for the #InternalMedicine Royal College exam here in Canada. #cardiosky #medsky #IMsky

#ASHKudos to super talented MD/PhD student Amara Pang on her Graduate Award from @ash-hematology.bsky.social. She has launched a fantastic new project in the lab on Kit-mutant mastocytosis! #ASH24

Beautiful piece honoring a brilliant and elegant physician and innovator. #bmtsm #celltherapy #ASH24

GoodMorning #ASHDash2024! So fun to see friends and faculty running this morning in SadDiego #SpeedRunners!! 🏃‍♂️

Send your malignant hematology work presented at #ASH24 to @bloodneoplaisa.bsky.social, Editor-in-chief Jonathan Licht @jdlicht.bsky.social and I look forward to helping you publish your work #bloodjournals

#ASH24 news: Universal Duffy Testing is Likely Cost Effective for U.S. Population: bit.ly/3CZbboM #HemeSky #Hematology

Dr. Stone from @danafarber.bsky.social presents on 10-year f/u of C10603/RATFIY trial investigating 7+3+mido vs 7+3 in ND FLT3m AML in pts age 18-60. OS benefit holds at 10 year follow-up including across subgroups. Mido exposure seemed protective in those receiving CR1 transplants.1/2 #ash24 #leusm

Cycle length notably higher in triplet recipients (aza/ven/ivo vs ven/ivo) due to cytopenias. Some heterogeneity in enrollees here (e.g. non-blast phase PV/MF in addition to AML) but encouraging. Question from audience on tx-free remission; MRD may help stratify. 2/2 #ASH24 #leusm

Dr. Jennifer Marvin-Peek from @mdanderson.bsky.social presents on results from 56 pts treated on a mulitcenter ph 1b/II study of VEN + IVO ± AZA for IDH1m AML (ND unfit or R/R) or HR MDS or MPN. In ph II, aza x14d, ven x14d continuous ivo used. CRc high w/ MDS/MPN and ND AML. (1/x) #ASH24 #leusm

Almost daily there is a new heritable BMF gene. ERCC6L2 is one of these new kids on the block. Sometimes it takes a bit to stress a stem cell, but when you do it right as Roman Schimmer has, TP53 (yes, that gene again) pops out as a (maladaptive) compensatory pathway. #ASH24 #HemeSky

Dr. Xueqing Dou discusses KIT/PDGFRA inhibitor avapritinib in 40 pts w/ core binding factor (CBF) AML w/ KIT mutations (possible higher risk of relapse) w/ R/R disease (n=12) or persistent MRD (n=28). 60% had ≥1-log MRD reduction as best response. Faster responses w/ t(8;21) (1/x) #ash24 #leusm

🩸Follow along the brillance at the 66th ASH Annual Meeting and Exposition Official feed: ✅ bsky.app/profile/did:... @ash-hematology.bsky.social @rubenmesamd.bsky.social @mpndoc.bsky.social @jennyruizmd.bsky.social @shematologist.bsky.social @carrawayhetty.bsky.social #ASH24 #HemeSky #MedSky

Amazing faculty headed to guide fellows at the #CareerDevelopmentLunch #ASH2024 #❤️hematology

Inspired at AshaPalooza with the launch of #HeartsofHeme and the ASH TraineeCouncil members ❤️❤️❤️

On my way to ASH Can’t wait to meet heme trainees ASH-a-Palooza! 🩸🎉🩸 #ASHaiku #HemeSky #ASHHFFTP @ash-hematology.bsky.social

On my way to ASH 2024 - Excited to see everyone there!! If you’re a trainee, don’t miss ASH-a-Palooza tomorrow starting at noon on 5th Ave between J & K street!

We just opened a search for a lab-based faculty position at Dana-Farber @danafarber.bsky.social @harvardmed.bsky.social Any area of cancer research is fair game and MD, PhD, or MD/PhD are encouraged to apply. Please spread the word: www.nejmcareercenter.org/job/829239/l...

If you’re at #ASH2024, make sure to check out the talk of Nithya Balasundaram from our lab on targeting mitochondria to increase STING signaling and immune-mediated AML cell elimination! Paper 827: Monday, December 9, 2024: 3:45 PM, Seaport Ballroom ABCD!

A highly anticipated new CAR-T cell therapy for B-cell ALL and a great news for the patients! Congratulations to Claire Roddie and the team behind the FELIX trial, leading to the FDA approval of Obecabtagene autoleucel. Read the full article here: www.nejm.org/doi/full/10....

I was deeply disappointed by the lack of nature/science/climate/enviro on many major end-of-year book lists—so I decided to make my own! Introducing: ✨🎁📚 The 2024 Holiday Gift Guide to Nature & Science Books ✨🎁📚 Please share: Let's make this go viral in time for Black Friday / holiday shopping!

Obe-cel resulted in a high incidence of durable response among adults with relapsed or refractory B-cell ALL, with a low incidence of grade 3 or higher immune-related toxic effects #leusm #cartcell www.nejm.org/doi/full/10....

#HeartsofHeme is a new series by ASH that features amazing stories by the people who make the #hematology and #hemeonc fields so special. Check out our latest story! #ASHTrainee #HemeSky #BloodSky #MedSky #OncSky www.linkedin.com/pulse/johns-...